Prognostic impact of hormone and HER2 status on the prognosis of breast cancer in Mosul

Abstract

Currant molecular classification of breast cancer based on Estrogen receptor (ER), Progesterone receptor (PR) and HER2 for gene expression is widely used for determining treatment approach for patients with breast cancer, our aims were to discover whether the molecular classification of breast cancer provides more information regarding survival compared to conventional histopathological prognostic factors. In this study we analyze the prognostic impact of ER, PR and HER2 expression using immunohistochemical study in breast cancer patients (n=152) independently and combined to gather, Survival analysis was done using Kaplan-Meier and Cox proportional hazards models adjusting for patient age, stage of the breast cancer. Molecular classification of breast cancer based on the pattern of expression of ER, PR, and HER2 was done. ER+/ PR+/ HER2- a subtype of breast cancer was found in 40.7% of cases, ER +/ PR+/ HER2 + was observed in 28% of the cases, ER-/ PR- / HER+ was found in 12.5% and finally, triple-negative subtype was found in 17.7% of the cases. Our result demonstrated that patients with different expressions of ER, PR, and HER2 have a different clinical outcome with different responses to treatment. Patients with ER+/ PR+/ HER2 - tumor have a favorable prognosis while patients with triple-negative tumors have the worst prognosis. Therefore, we recommend using this molecular classification in all patients with breast cancer for selecting the appropriate treatment approach.